| HOME >> BIOLOGY >> TECHNOLOGY |
DENVER and GOLDEN, Colo., Nov. 30 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today the company's continued support for the American Society for Cell Biology's 47th Annual Meeting in Washington D.C., December 1 - 5, 2007.
"The ASCB meeting is one of the most significant of the year in terms of contact with our customer base and we feel privileged to participate in this exciting area of research," said Ken Wilczek, President of ABR. "The opportunity to support cell biology research in all of its various facets is of great value to us at ABR. We welcome the chance to participate in discussions with preeminent scientists and researchers who help to shape policy with regard to future direction in this research area," noted Mr. Wilczek.
ABR now offers over 2,500 products for cell biology research, all of which are supported by ABR's 100% Quality Guarantee. "Cell Biology is a key and growing research focus for ABR, with several new and notable products launched in advance of this meeting," noted Mr. Wilczek. Advances in cell biology have been remarkable in recent years, and ABR is at the forefront of this research with a comprehensive line of "off the shelf" and custom antibody products specifically developed to meet and exceed the needs of the life science researcher who focuses on cell biology. ABR-Affinity BioReagents will be located at booth #1154 at The American Society for Cell Biology's 47th Annual Meeting.
About ABR-Affinity BioReagents
Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).
With more than 35,000 antibodies focused in 43 research areas, ABR
offers a unique value proposition in the life science industry-research
antibodies that are
'/>"/>
| SOURCE ABR-Affinity BioReagents Copyright©2007 PR Newswire. All rights reserved |